

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2015.

Commission File Number: 001-37384

GALAPAGOS NV
(Translation of registrant's name into English)

Generaal De Wittelaan L11 A3
2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [x] Form 40-F []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ___

On November 20, 2015 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

<u>Exhibit</u>	<u>Description</u>
99.1	Press release dated November 20, 2015
99.2	Notification of participation
99.3	Invitation to the Special Shareholders' Meeting to be held on 22 December 2015
99.4	Proxy
99.5	Shares and Voting Rights

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GALAPAGOS NV
(Registrant)

Date: November 24, 2015

/s/ XAVIER MAES
Xavier Maes
Company Secretary

Invitation to the Special Shareholders' Meeting of Galapagos on 22 December 2015

Mechelen, Belgium; 20 November 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) has the honor to invite the Shareholders, Warrant Holders, Directors and Statutory Auditor of the Company to a Special Shareholders' Meeting that will be held on Tuesday 22 December 2015 at 2:00 p.m. (CET) at the registered office of the Company.

In order to be admitted to the Shareholders' Meeting, the holders of securities issued by the Company must comply with article 536 of the Belgian Companies Code and article 29 of the articles of association of the Company, and fulfill the formalities and make the notifications described in the convening notice.

The convening notice and other relevant documents can be found at <http://www.glp.com/shareholders-meetings>.

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, three Phase 1 trials, four pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases. Galapagos has reported good activity and a favorable safety profile in both the DARWIN 1 and 2 trials in RA. Galapagos is preparing to enter Phase 3 studies in RA and to report Phase 2 topline results with filgotinib in Phase 2 in Crohn's disease. In the field of cystic fibrosis, AbbVie and Galapagos collaborate to develop and commercialize molecules that address mutations in the CFTR gene. Further clinical trial initiations are expected in the CF program before end 2015. GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned by Galapagos, will report topline results in Q4 2015 from a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown favorable safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary fibrosis. GLPG1972 is a novel mode of action candidate drug currently in Phase 1, with potential application in osteoarthritis. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More info at www.glp.com.

Kennisgeving van deelname

Notification of participation

(enkel te gebruiken door houders van aandelen op naam en houders van warrants op naam)

(to be used by holders of registered shares and holders of registered warrants only)

De ondergetekende:

The undersigned:

(Naam en adres / Name and address)

heeft kennis genomen van de Bijzondere Algemene Vergadering van **Galapagos NV** (naamloze vennootschap naar Belgisch recht met zetel te Generaal De Wittelaan L11 A3, 2800 Mechelen, België, ingeschreven in het Rechtspersonenregister (Antwerpen, afdeling Mechelen) onder nummer 0466.460.429) (de "**Vennootschap**"),

has taken notice of the Special Shareholders' Meeting of **Galapagos NV** (public limited liability company organized under the laws of Belgium with registered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium, registered with the Register of Legal Entities (Antwerp, division Mechelen) under number 0466.460.429) (the "**Company**"),

die zal plaatsvinden op dinsdag 22 december 2015 om 14 uur op de zetel van de Vennootschap,

to be held on Tuesday 22 December 2015 at 2:00 p.m. (CET) at the registered office of the Company,

en brengt de Vennootschap hierbij op de hoogte van zijn/haar voornemen om aan deze Algemene Vergadering deel te nemen,

and hereby notifies the Company of his/her/its intention to participate in this Shareholders' Meeting,

met de volgende effecten:

with the following securities:

aandelen op naam; en/of	registered shares, and/or
(Aantal)	(Number)
warrants van de Vennootschap.	warrants of the Company.
(Aantal)	(Number)

(Datum / Date)

(Naam / Name)

(Handtekening / Signature)

De ondertekende kennisgeving dient **uiterlijk op 16 december 2015** toe te komen op de zetel van Galapagos NV. Het dient te worden overgemaakt per e-mail (shareholders@glpg.com) of met de post (Galapagos NV, t.a.v. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, België).

The signed notification must be received **at the latest on 16 December 2015** at the registered office of Galapagos NV. It should be submitted by e-mail (shareholders@glpg.com) or by post (Galapagos NV, attn. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium).

Aandeelhouders die wensen deel te nemen of zich te laten vertegenwoordigen moeten tevens voldoen aan de toelatingsvoorwaarden zoals beschreven in de oproeping tot de Bijzondere Algemene Vergadering.

Shareholders who wish to attend or to be represented by proxy must also comply with the admission conditions as described in the convening notice to the Special Shareholders' Meeting.

GALAPAGOS
 Limited Liability Company
 Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
 Company Number: 0466.460.429
 RLE Antwerp (division Mechelen)

Invitation to the Special Shareholders' Meeting to be held on 22 December 2015

The Board of Directors of Galapagos NV (hereinafter the “**Company**” or “**Galapagos**”) has the honor to invite the Shareholders, Warrant Holders, Directors and Statutory Auditor of the Company to the Special Shareholders' Meeting that will be held on Tuesday 22 December 2015 at 2:00 p.m. (CET) at the registered office of the Company.

Agenda and proposed resolutions

1. Confirmation of appointment of Independent Director.

Proposed resolution: The Shareholders' Meeting resolves to confirm the appointment of Dr. Christine Mummery (residing in Bilthoven, The Netherlands) as a Director of the Company, made by the Board as from 30 September 2015 to fill a vacancy, and to appoint her as a Director of the Company for a period of four years ending immediately after the Shareholders' Meeting in 2019 which has the approval of the annual accounts on its agenda. Upon the proposal of the Board and in accordance with the advice of the Company's Nomination and Remuneration Committee, the Shareholders' Meeting further resolves to appoint Dr. Mummery as an Independent Director as she meets the criteria of independence set forth in article 526ter of the Belgian Companies Code and Dr. Mummery expressly stated, and as far as the Board is aware, she does not have any relationship with any company that would compromise her independence.

The Shareholders' Meeting acknowledges that the Board may determine the remuneration to be granted to Dr. Mummery for the exercise of her mandate as a Director of the Company within the limits of the power of attorney unanimously approved by the Shareholders' Meeting on 28 April 2015 (*eighth agenda item – Remuneration of Directors*).

2. Offer of warrants.

Proposed resolution: The Shareholders' Meeting resolves to approve the proposal of the Company's Nomination and Remuneration Committee to offer additional warrants to the Company's Directors in light of an independent benchmarking exercise and recommendation by an external advisor, following the growth of the Company and the recent US listing of the Company on Nasdaq and consequently (i) resolves to offer 100,000 warrants to Mr. Onno van de Stolpe, 15,000 warrants to Dr. Raj Parekh, and 7,500 warrants to each of Dr. Werner Cautreels, Dr. Harrold van Barlingen, Mr. Howard Rowe, Ms. Katrine Bosley and Dr. Christine Mummery, under warrant plans to be created by the Board of Directors for the benefit of Directors, employees and independent consultants of Galapagos and its affiliates within the framework of the authorized capital (jointly “Warrant Plan 2015 (B)”), the key conditions of which will be in line with previous warrant plans of the Company, (ii) empowers the Managing Director, as well as any other Director as regards the offer to the Managing Director, to implement this offer, and (iii) to the extent required, approves the offer of warrants to members of Galapagos' Executive Committee under Warrant Plan 2015 (B) in accordance with Galapagos' remuneration policy and practices. In accordance with articles 520ter and 556 of the Belgian Companies Code, the Shareholders' Meeting expressly approves the particular provisions of such Warrant Plan 2015 (B) pursuant to which, in exceptional circumstances (including in the event of a change in control of the Company), all 700,000 warrants offered (to the extent accepted) under Warrant Plan 2015 (B) can be exercised early, even before the third anniversary of their award.

The resolutions of this Shareholders' Meeting relating to the issuance of warrants can only be implemented if the Belgian Financial Services and Markets Authority (FSMA) has communicated to the Company that it has no objections to make against the issuance of warrants as set forth in this agenda item.

Registration and admission formalities

In order to be admitted to the Shareholders' Meeting, the holders of securities issued by the Company must comply with article 536 of the Belgian Companies Code and article 29 of the articles of association of the Company, and fulfill the formalities and make the notifications described below.

In accordance with article 537 of the Belgian Companies Code, the holders of warrants issued by the Company can only attend the Shareholders' Meeting with a consultative vote.

1 Holders of registered shares and warrants

The holders of registered shares and warrants are entitled to participate in and, in the case of shares, to vote at the Shareholders' Meeting, provided that:

- their shares or warrants are recorded in their name in the register of registered shares or warrants at midnight (24:00) (CET) on 8 December 2015 (the "**record date**"), irrespective of the number of shares or warrants that they own on the date of the Shareholders' Meeting; and
- they notify the Company in writing of (i) their intention to participate in the Shareholders' Meeting, and (ii) the number of securities for which they wish to participate in the Shareholders' Meeting, by means of a signed form that must be received by the Company at the Company's registered office **at the latest on 16 December 2015**; a model of this form is available at the Company's registered office and on the Company's website under the tab "Investors > Shareholder Information > Shareholders' Meetings" (www.glpq.com).

This notification must be submitted to Galapagos by e-mail (shareholders@glpq.com) or by post (Galapagos NV, attn. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium).

2 Holders of dematerialized shares

The holders of dematerialized shares are entitled to participate in and to vote at the Shareholders' Meeting, provided that:

- their shares are recorded in their name in the accounts of a recognized account holder or a settlement institution at midnight (24:00) (CET) on 8 December 2015 (the "**record date**"), irrespective of the number of shares that they own on the date of the Shareholders' Meeting; and
- **at the latest on 16 December 2015**, they provide the Company (at the Company's registered office) with, or arrange for the Company (at the Company's registered office) to be provided with, a certificate issued by a recognized account holder or the settlement institution certifying the number of dematerialized shares recorded in the shareholder's accounts on the record date in respect of which the shareholder has indicated his intention to participate in the Shareholders' Meeting.

This certificate must be submitted to Galapagos by e-mail (shareholders@glpq.com) or by post (Galapagos NV, attn. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium).

Only persons who are a shareholder of the company on the record date (8 December 2015) and who have indicated their intention to participate in the Shareholders' Meeting as set out above will be entitled to participate in the Shareholders' Meeting. The shares are not blocked as a result of the above-mentioned process. As a result, the shareholders are free to dispose of their shares after the record date.

Proxy

In accordance with article 30 of the articles of association of the Company, shareholders having complied with the registration and admission formalities set out above may be represented at the Shareholders' Meeting by a proxy holder, who does not need to be a shareholder. Except in cases provided for by law, a shareholder may only appoint one person as proxy holder for a particular Shareholders' Meeting.

Shareholders who so wish to be represented by proxy should use the proxy form (with voting instructions) made available at the Company's registered office and on the Company's website under the tab "Investors > Shareholder Information > Shareholders' Meetings" (www.glpj.com).

The signed proxy form must be submitted to Galapagos by e-mail (shareholders@glpj.com) or by post (Galapagos NV, attn. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium), and must reach Galapagos by **no later than 16 December 2015**.

Right to ask questions

In accordance with article 540 of the Belgian Companies Code and article 34 of the articles of association of the Company, all shareholders are entitled, whether during the Shareholders' Meeting or in writing before the Meeting, to ask questions to the Directors with respect to their report or the agenda items and to the Statutory Auditor with respect to its report (if applicable).

Questions asked in writing will only be answered if the relevant shareholder has fulfilled the registration and admission formalities set out above and if the written question has been received by the Company **at the latest on 16 December 2015**.

Such questions must be submitted to Galapagos by e-mail (shareholders@glpj.com) or by post (Galapagos NV, attn. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium).

Right to add agenda items

In accordance with article 533ter of the Belgian Companies Code and article 28 of the articles of association of the Company, one or more shareholders, who together possess at least three per cent (3%) of the Company's share capital, may request for items to be added to the agenda of the Shareholders' Meeting and submit proposed resolutions in relation to existing agenda items or new items to be added to the agenda. Such requests, along with proof of ownership of the required participation, and, as the case may be, the text of the items to be dealt with and the related proposed resolutions, must be submitted to Galapagos by e-mail (shareholders@glpj.com) or by post (Galapagos NV, attn. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium), and must reach Galapagos by **no later than 30 November 2015**. As the case may be, Galapagos shall publish the modified agenda at the latest on 7 December 2015.

Availability of documents

The documentation relating to this Shareholders' Meeting or that must be made available pursuant to law, as well as the total number of shares and voting rights at the date of the convening notice, are available on the Company's website under the tab "Investors > Shareholder Information > Shareholders' Meetings" (www.glpj.com). Hard copies of these documents can be obtained at no cost by simple request via e-mail (shareholders@glpj.com), post (Galapagos NV, attn. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium), or telephone (+32 15 342 979). Please address any requests for more information to Galapagos' Legal Department (Phone: +32 15 342 979). Correspondence can be sent to Galapagos NV, attn. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (e-mail: shareholders@glpj.com).

Miscellaneous

In order to facilitate an expedient registration, the participants are requested to be present at least fifteen minutes prior to the start of the Shareholders' Meeting.

The natural persons who intend to attend the Shareholders' Meeting in their capacity of owners of securities, proxy holders or representatives of a legal entity must be able to provide evidence of their identity in order to be granted access to the Shareholders' Meeting. The representatives of legal entities must hand over the documents establishing their capacity as corporate representative or attorney-in-fact. These documents will be verified immediately before the start of the Meeting.

The Board of Directors

Volmacht
(enkel te gebruiken door Aandeelhouders)

Proxy
(to be used by Shareholders only)

De ondergetekende:

The undersigned:

(Naam en adres / Name and address)

hierin optredend als lastgever,

herein acting as grantor of a proxy,

eigenaar van het volgende aantal aandelen in **Galapagos NV** (naamloze vennootschap naar Belgisch recht met zetel te Generaal De Wittelaan L11 A3, 2800 Mechelen, België, ingeschreven in het Rechtspersonenregister (Antwerpen, afdeling Mechelen) onder nummer 0466.460.429) (de “**Vennootschap**”):

owner of the following number of shares in **Galapagos NV** (public limited liability company organized under the laws of Belgium with registered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium, registered with the Register of Legal Entities (Antwerp, division Mechelen) under number 0466.460.429) (the “**Company**”):

(Aantal aandelen / Number of shares)

stelt hiermee aan tot zijn/haar volmachtdrager:

herewith appoints as his/her proxy holder:

(Naam en adres van de gevolmachtigde / Name and address of the proxy holder)

(Indien de naam van de volmachtdrager niet is ingevuld, zal de volmacht geacht worden te zijn gegeven aan de Senior Counsel van de Vennootschap) (If the name of the proxy holder is not completed, the proxy will be deemed to be given to the Senior Counsel of the Company)

hierna de “**volmachtdrager**”,

hereinafter the “**proxy holder**”,

aan wie hij/zij volmacht geeft tot bijwonen van en om stemrechten uit te oefenen tijdens de Bijzondere Algemene Vergadering van de Vennootschap die zal plaatsvinden op dinsdag 22 december 2015 om 14 uur op de zetel van de Vennootschap, alsmede elke andere aandeelhoudersvergadering met dezelfde agenda die daarna zou worden bijeengeroepen als gevolg van uitstel of verdaging, met als bedoeling de hierna uiteengezette agenda in overweging te nemen en om, voor dit doel, deel te nemen aan alle activiteiten, te stemmen of zich te onthouden, notulen en andere stukken te ondertekenen, woonplaats te kiezen, subdelegatie te geven, en meer in het algemeen te doen wat nuttig of noodzakelijk wordt geacht door de volmachtdrager.

to whom he/she gives power of attorney to attend and exercise voting rights at the Special Shareholders’ Meeting of the Company to be held on Tuesday 22 December 2015 at 2:00 p.m. CET at the registered office of the Company, as well as at any other shareholders’ meeting with the same agenda that may be convened subsequently as a result of delay or adjournment, for the purpose of considering the agenda set forth below, and for this purpose, to take part in all proceedings, to vote or abstain, to sign any minutes and other items, to elect domicile, to sub-delegate authority, and more generally to do anything the proxy holder deems useful or necessary.

Indien overeenkomstig artikel 533ter van het Wetboek van vennootschappen nieuw te behandelen onderwerpen op de agenda zijn opgenomen nadat onderhavige volmacht ter kennis van de Vennootschap is gebracht, zal de volmachtdrager ook voor deze nieuwe agendapunten kunnen stemmen zover de volmachtdrager daarbij geen ander belang dan het belang van ondergetekende aandeelhouder nastreeft.

If pursuant to article 533ter of the Belgian Companies Code new items to be dealt with are included in the agenda after the present proxy form has been submitted to the Company, the proxy holder shall be entitled to vote for such new agenda items insofar the proxy holder, by doing so, does not pursue another interest than the interest of the undersigned shareholder.

Agenda

1. Bevestiging van benoeming Onafhankelijke Bestuurder.

Voorstel van besluit: De Algemene Vergadering besluit om de benoeming als Bestuurder van de Vennootschap van Dr. Christine Mummery (wonende te Bithoven, Nederland) door de Raad van Bestuur ter invulling van een vacature, met ingang vanaf 30 september 2015, te bekrachtigen en om haar te benoemen als Bestuurder van de Vennootschap voor een periode van vier jaar die een einde neemt onmiddellijk na de Algemene Vergadering in 2019 die de goedkeuring van de jaarrekening op haar agenda heeft. Op voorstel van de Raad van Bestuur en in overeenstemming met het advies van het Benoemings- en Remuneratiecomité van de Vennootschap, besluit de Algemene Vergadering verder om Dr. Mummery te benoemen als Onafhankelijke Bestuurder aangezien zij voldoet aan de onafhankelijkheidscriteria uiteengezet in artikel 526ter van het Wetboek van vennootschappen en Dr. Mummery uitdrukkelijk heeft verklaard geen (en de Raad evenmin op de hoogte is van enige) banden met een vennootschap te hebben die haar onafhankelijkheid in het gedrang zouden brengen.

De Algemene Vergadering erkent dat de Raad van Bestuur de bezoldiging mag bepalen die aan Dr. Mummery zal worden toegekend voor de uitoefening van haar mandaat als Bestuurder van de Vennootschap, binnen de grenzen van de volmacht die unaniem werd goedgekeurd door de Algemene Vergadering gehouden op 28 april 2015 (*achtste agendapunt – Bezoldiging van Bestuurders*).

1. Confirmation of appointment of Independent Director.

Proposed resolution: The Shareholders' Meeting resolves to confirm the appointment of Dr. Christine Mummery (residing in Bithoven, The Netherlands) as a Director of the Company, made by the Board as from 30 September 2015 to fill a vacancy, and to appoint her as a Director of the Company for a period of four years ending immediately after the Shareholders' Meeting in 2019 which has the approval of the annual accounts on its agenda. Upon the proposal of the Board and in accordance with the advice of the Company's Nomination and Remuneration Committee, the Shareholders' Meeting further resolves to appoint Dr. Mummery as an Independent Director as she meets the criteria of independence set forth in article 526ter of the Belgian Companies Code and Dr. Mummery expressly stated, and as far as the Board is aware, she does not have any relationship with any company that would compromise her independence.

The Shareholders' Meeting acknowledges that the Board may determine the remuneration to be granted to Dr. Mummery for the exercise of her mandate as a Director of the Company within the limits of the power of attorney unanimously approved by the Shareholders' Meeting on 28 April 2015 (*eighth agenda item – Remuneration of Directors*).

Agendapunt 1 - Stemstructuur:



Voor / In favor



Tegen / Against



Onthouding / Abstention

Agenda item 1 - Voting instruction:

2. Aanbod van warrants.

Voorstel van besluit: De Algemene Vergadering besluit om het voorstel van het Benoemings- en Remuneratiecomité van de Vennootschap goed te keuren om bijkomende warrants aan de Bestuurders van de Vennootschap aan te bieden gelet op de bevindingen van een onafhankelijke vergelijkende studie en de aanbevelingen van een externe adviseur volgend op de recente notering van de Vennootschap in de Verenigde Staten op Nasdaq en de groei van de Vennootschap. De Algemene Vergadering besluit bijgevolg: (i) om 100.000 warrants aan te bieden aan Dhr. Onno van de Stolpe, 15.000 warrants aan Dr. Raj Parekh, en 7.500 warrants aan elkeen van Dr. Werner Cautreels, Dr. Harrold van Barlingen, Dhr. Howard Rowe, Mw. Katrine Bosley en Dr. Christine Mummery, onder warrantplannen te creëren door de Raad van Bestuur ten gunste van de Bestuurders, werknemers en zelfstandige consulenten van Galapagos en haar dochtervennootschappen in het kader van het toegestaan kapitaal (samen "Warrantplan 2015 (B)"), waarvan de voornaamste voorwaarden in lijn zullen zijn met de voorgaande warrantplannen van de Vennootschap, (ii) om volmacht te geven aan de Gedelegeerd Bestuurder, alsmede aan elke andere Bestuurder voor wat betreft het aanbod aan de Gedelegeerd Bestuurder zelf, om dit aanbod te implementeren, en (iii) om, voor zover als nodig, het aanbod goed te keuren van warrants aan leden van het Directiecomité van Galapagos onder Warrantplan 2015 (B) overeenkomstig het remuneratiebeleid en de remuneratiepraktijken van Galapagos. Overeenkomstig artikels 520ter en 556 van het Wetboek van vennootschappen, keurt de Algemene Vergadering uitdrukkelijk de bijzondere bepalingen van dergelijk Warrantplan 2015 (B) goed waarbij, in uitzonderlijke omstandigheden (waaronder in geval van wijziging in de controle van de Vennootschap), alle 700.000 warrants die worden aangeboden onder Warrantplan 2015 (B) (in de mate waarin deze ook worden aanvaard) vervroegd kunnen worden uitgeoefend, zelfs vóór de derde verjaardag van de toekenning ervan.

De besluiten van deze Algemene Vergadering met betrekking tot de uitgifte van warrants kunnen slechts worden uitgevoerd indien de Autoriteit voor Financiële Diensten en Markten (FSMA) aan de Vennootschap heeft meegedeeld geen bezwaar te moeten maken tegen de in dit agendapunt opgenomen uitgifte van warrants.

2. Offer of warrants.

Proposed resolution: The Shareholders' Meeting resolves to approve the proposal of the Company's Nomination and Remuneration Committee to offer additional warrants to the Company's Directors in light of an independent benchmarking exercise and recommendation by an external advisor, following the growth of the Company and the recent US listing of the Company on Nasdaq and consequently (i) resolves to offer 100,000 warrants to Mr. Onno van de Stolpe, 15,000 warrants to Dr. Raj Parekh, and 7,500 warrants to each of Dr. Werner Cautreels, Dr. Harrold van Barlingen, Mr. Howard Rowe, Ms. Katrine Bosley and Dr. Christine Mummery, under warrant plans to be created by the Board of Directors for the benefit of Directors, employees and independent consultants of Galapagos and its affiliates within the framework of the authorized capital (jointly "Warrant Plan 2015 (B)"), the key conditions of which will be in line with previous warrant plans of the Company, (ii) empowers the Managing Director, as well as any other Director as regards the offer to the Managing Director, to implement this offer, and (iii) to the extent required, approves the offer of warrants to members of Galapagos' Executive Committee under Warrant Plan 2015 (B) in accordance with Galapagos' remuneration policy and practices. In accordance with articles 520ter and 556 of the Belgian Companies Code, the Shareholders' Meeting expressly approves the particular provisions of such Warrant Plan 2015 (B) pursuant to which, in exceptional circumstances (including in the event of a change in control of the Company), all 700,000 warrants offered (to the extent accepted) under Warrant Plan 2015 (B) can be exercised early, even before the third anniversary of their award.

The resolutions of this Shareholders' Meeting relating to the issuance of warrants can only be implemented if the Belgian Financial Services and Markets Authority (FSMA) has communicated to the Company that it has no objections to make against the issuance of warrants as set forth in this agenda item.

Agendapunt 2 - Steminstructie:

Voor / In favor
Agenda item 2 - Voting instruction:

Tegen / Against

Onthouding / Abstention
Ondergetekende is er uitdrukkelijk mee akkoord dat:

(i) bij afwezigheid van steminstructies voor enig agendapunt of in het geval dat er, om welke reden dan ook, enige onduidelijkheid zou ontstaan betreffende de steminstructies, de volmachthouder altijd “voor” het voorstel tot besluit zal stemmen voor deze punten waarvoor geen of een onduidelijke steminstructie is gegeven en dat dit een specifieke steminstructie geacht zal zijn in de zin van artikel 547bis §4 2° van het Wetboek van vennootschappen;

(ii) in geval de naam van de volmachtdrager niet is ingevuld, de volmacht geacht zal worden gegeven te zijn aan de Senior Counsel van Galapagos NV, die een werknemer is van Galapagos NV maar geen lid van haar Raad van Bestuur of haar Directiecomité;

Onderhavige volmacht geldt tevens als aanmelding in de zin van artikel 536 van het Wetboek van vennootschappen.

The undersigned expressly agrees that:

(i) in the absence of voting instructions for any agenda item or in the event that, for any reason whatsoever, any uncertainty would arise with regards to the voting instructions, the proxy holder will always vote “in favor” of the proposal for such items for which no or an unclear voting instruction is given and that this will be deemed to be a specific voting instruction in the sense of article 547bis §4 2° of the Belgian Companies Code;

(ii) in the event the name of the proxy holder is not completed, the proxy will be deemed to be given to the Senior Counsel of Galapagos NV, who is an employee of Galapagos NV but not a member of its Board of Directors or of its Executive Committee.

The present proxy shall also serve as notification within the meaning of article 536 of the Belgian Companies Code.

Goed voor volmacht:**Good for proxy:**

 (Datum / Date)

 (Naam / Name)

 (Handtekening / Signature)

Het ondertekende volmachtformulier dient **uiterlijk op 16 december 2015** toe te komen op de zetel van Galapagos NV. Het dient te worden overgemaakt per e-mail (shareholders@glpg.com) of met de post (Galapagos NV, t.a.v. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, België).

Aandeelhouders die zich wensen te laten vertegenwoordigen moeten tevens voldoen aan de toelatingsvoorwaarden zoals beschreven in de oproeping tot de Bijzondere Algemene Vergadering.

The signed proxy form must be received **at the latest on 16 December 2015** at the registered office of Galapagos NV. It should be submitted by e-mail (shareholders@glpg.com) or by post (Galapagos NV, attn. Xavier Maes, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium).

Shareholders who wish to be represented by proxy must also comply with the admission conditions as described in the convening notice to the Special Shareholders' Meeting.

GALAPAGOS

Naamloze Vennootschap / Limited Liability Company
Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
RPR / RLE (Antwerp, division Mechelen) 0466.460.429

Op 20 november 2015 bedraagt het totaal aantal aandelen en stemrechten van Galapagos NV
39.012.842

On 20 November 2015, the total number of shares and voting rights of Galapagos NV amounts to
39,012,842